Global cancer in women: burden and trends
This review is an abbreviated version of a report prepared for the American Cancer Society
Global Health department and EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt …
Global Health department and EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt …
Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience
SM Garland, SK Kjaer, N Muñoz… - Reviews of Infectious …, 2016 - academic.oup.com
Prophylactic human papillomavirus (HPV) vaccination programs constitute major public
health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) …
health initiatives worldwide. We assessed the global effect of quadrivalent HPV (4vHPV) …
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income …
Summary Background The WHO Director-General has issued a call for action to eliminate
cervical cancer as a public health problem. To help inform global efforts, we modelled …
cervical cancer as a public health problem. To help inform global efforts, we modelled …
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
WK Huh, EA Joura, AR Giuliano, OE Iversen… - The Lancet, 2017 - thelancet.com
Background Primary analyses of a study in young women aged 16–26 years showed
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52 …
[HTML][HTML] Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices
E Petrosky, JA Bocchini Jr, S Hariri, H Chesson… - MMWR Morb Mortal …, 2015 - cdc.gov
Methods From October 2013 to February 2015, the ACIP HPV Vaccine Work Group
reviewed clinical trial data assessing the efficacy, immunogenicity, and safety of 9vHPV …
reviewed clinical trial data assessing the efficacy, immunogenicity, and safety of 9vHPV …
[HTML][HTML] A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
EA Joura, AR Giuliano, OE Iversen… - … England Journal of …, 2015 - Mass Medical Soc
Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …
US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines
M Saraiya, ER Unger, TD Thompson… - Journal of the …, 2015 - academic.oup.com
Background: This study sought to determine the prevaccine type-specific prevalence of
human papillomavirus (HPV)–associated cancers in the United States to evaluate the …
human papillomavirus (HPV)–associated cancers in the United States to evaluate the …
[HTML][HTML] Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
Prevalence of HPV after introduction of the vaccination program in the United States
LE Markowitz, G Liu, S Hariri, M Steinau, EF Dunne… - …, 2016 - publications.aap.org
BACKGROUND: Since mid-2006, human papillomavirus (HPV) vaccination has been
recommended for females aged 11 to 12 years and through 26 years if not previously …
recommended for females aged 11 to 12 years and through 26 years if not previously …
[HTML][HTML] Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva
S De Sanjosé, L Alemany, J Ordi, S Tous… - European journal of …, 2013 - Elsevier
Background Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN)
and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data …
and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data …